Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
In recent years, circulating tumor DNA (ctDNA)had achieved encouraging results in monitoring
recurrence and metastasis after surgery, and has potential clinical application value. The
presence of ctDNA after surgery predicts very poor recurrence-free survival, whereas its
absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for
ctDNA-positive patients is not well understood.